HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 31/4/759    most recent 09031936.00114207v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Rietema, H. Articles by Vonk-Noordegraaf, A. Search for Related Content PubMed PubMed Citation Articles by Rietema, H. Articles by Vonk-Noordegraaf, A.

Sildenafil treatment in COPD does not affect stroke volume or exercise capacity

Dept of Pulmonary Diseases and Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.

CORRESPONDENCE: A. Vonk-Noordegraaf, Dept of Pulmonology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Fax: 31 204444328. E-mail: a.vonk{at}vumc.nl

Keywords: Chronic obstructive pulmonary disease, magnetic resonance imaging, pulmonary hypertension, sildenafil, stroke volume

Received: August 31, 2007
Accepted November 27, 2007

In chronic obstructive pulmonary disease (COPD) patients, stroke volume response to exercise is impaired. The aim of the present study was to investigate whether 3 months of sildenafil treatment improves stroke volume and, if so, whether this improvement is related to the pulmonary artery pressure and translated into an improved exercise capacity.

A total of 15 stable COPD patients (Global Initiative for Chronic Obstructive Lung Disease stage II–IV) underwent right heart catheterisation at rest and during exercise. Stroke volume was assessed by magnetic resonance imaging (MRI) at rest and during submaximal exercise in the supine position and compared with eight age-matched controls. Additionally, a cardiopulmonary exercise test and a 6-min walking distance test were performed. Exercise tests and MRI were repeated after 12 weeks of oral therapy with 50 mg sildenafil three times daily.

Stroke volume in COPD patients was significantly lower than in healthy controls (62±12 versus 81±22 mL at rest and 70±15 versus 101±28 mL during exercise). Pulmonary hypertension (PH) was diagnosed in nine patients and was absent in six. Treatment with sildenafil had no effect on stroke volume or exercise capacity. Although the stroke volume was lower in COPD patients with associated PH in comparison with non-PH patients, there was no difference in treatment response between both groups.

In the present group of 15 chronic obstructive pulmonary disease patients, a reduced stroke volume was found at rest and during exercise. Neither stroke volume nor exercise capacity were improved by 3 months of sildenafil therapy.

This article has been cited by other articles:

				Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537. [Full Text] [PDF]

				M. W. Sims, D. J. Margolis, A. R. Localio, R. A. Panettieri, S. M. Kawut, and J. D. Christie Impact of Pulmonary Artery Pressure on Exercise Function in Severe COPD Chest, August 1, 2009; 136(2): 412 - 419. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, J. A. Barbera, R. N. Channick, P. M. Hassoun, I. M. Lang, A. Manes, F. J. Martinez, R. Naeije, H. Olschewski, J. Pepke-Zaba, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S85 - S96. [Abstract] [Full Text] [PDF]

				J. D Maclay, R. A Rabinovich, and W. MacNee Update in Chronic Obstructive Pulmonary Disease 2008 Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 533 - 541. [Full Text] [PDF]

				D. Stolz and M. Tamm From the authors Eur. Respir. J., February 1, 2009; 33(2): 452 - 453. [Full Text] [PDF]

				N. Galiè and A. Manes CHAPTER 24 Pulmonary Hypertension ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				A. Chaouat, R. Naeije, and E. Weitzenblum Pulmonary hypertension in COPD Eur. Respir. J., November 1, 2008; 32(5): 1371 - 1385. [Abstract] [Full Text] [PDF]

				C. Vassaux, L. Torre-Bouscoulet, S. Zeineldine, F. Cortopassi, H. Paz-Diaz, B. R. Celli, and V. M. Pinto-Plata Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD Eur. Respir. J., November 1, 2008; 32(5): 1275 - 1282. [Abstract] [Full Text] [PDF]

				M. M. Hoeper Treating pulmonary hypertension in COPD: where do we start? Eur. Respir. J., September 1, 2008; 32(3): 541 - 542. [Full Text] [PDF]